Researchers have developed a new glowing dye called JMR-1002-PEG that can detect liver damage by sensing changes in the liver’s microscopic environment. According to Gram Research analysis, this near-infrared dye successfully identified three types of liver damage in mice—acute injury, scarring, and fatty liver disease—with results matching standard diagnostic tests. The dye changes brightness based on how thick the fluid around liver cells becomes, offering a potential new way to spot liver problems earlier than current methods.
Scientists have created a special glowing dye that can detect liver damage in real-time by sensing changes in the liver’s tiny environment. According to Gram Research analysis, this new tool called JMR-1002-PEG uses near-infrared light to spot problems like fatty liver disease, liver scarring, and drug-related injury in living mice. The dye glows brighter or dimmer depending on how thick the fluid around liver cells becomes—a sign of damage. This breakthrough could eventually help doctors catch liver problems much earlier than current methods, potentially saving lives by enabling faster treatment.
Key Statistics
A 2026 research study published in ACS Sensors demonstrated that JMR-1002-PEG, a water-soluble near-infrared fluorescent dye, successfully detected liver damage in mice with acetaminophen-induced acute injury, carbon tetrachloride-induced fibrosis, and diet/drug-induced steatosis.
The new molecular rotor dye’s signal intensity correlated with standard biochemical and histological markers of liver damage in mice, and decreased after treatment was administered, suggesting potential for real-time monitoring of liver disease progression.
JMR-1002-PEG uses near-infrared II wavelengths (1000-1700 nanometers) for liver imaging, providing superior tissue penetration compared to previous visible-light molecular rotors, enabling detection of microviscosity changes in the hepatic microenvironment.
The Quick Take
- What they studied: Can a new glowing dye detect liver damage by measuring changes in how thick the fluid around liver cells becomes?
- Who participated: Laboratory mice with different types of liver damage: acetaminophen-induced acute injury, carbon tetrachloride-induced fibrosis, and diet/drug-induced fatty liver disease
- Key finding: The new dye successfully detected all three types of liver damage in mice, and the glow intensity matched standard medical tests used to diagnose liver problems
- What it means for you: This technology is still in early research stages with mice. If it advances to human testing and approval, it could eventually offer doctors a faster, non-invasive way to diagnose liver disease, though years of development remain before clinical use
The Research Details
Researchers designed a new fluorescent molecule—a special dye that glows under specific light—called JMR-1002-PEG. This dye was engineered to change its brightness based on the thickness (viscosity) of fluid in the liver’s microscopic environment. The team tested this dye in mice with three different types of liver damage: acute injury from acetaminophen (a common pain reliever), scarring from a toxic chemical, and fatty liver disease from diet and drugs.
The dye works using near-infrared light, which is invisible to human eyes but can penetrate deep into body tissues. When the dye is injected into mice, it accumulates in the liver and glows in response to changes in the liver’s cellular environment. The researchers compared the dye’s glow intensity to traditional blood tests and tissue samples to verify accuracy.
This approach is novel because most existing imaging tools can’t detect the subtle changes in liver tissue texture that happen during disease development. By measuring viscosity—how thick or thin the fluid is around liver cells—the dye provides a new window into liver health that wasn’t previously accessible.
Current methods for detecting liver disease rely on blood tests that show damage after it’s already occurred, or biopsies that require taking tissue samples. This new dye could enable real-time, non-invasive monitoring of liver health as it changes, potentially catching disease at earlier, more treatable stages. The ability to see what’s happening inside the liver without surgery is a significant advantage for both diagnosis and monitoring treatment effectiveness.
This is a proof-of-concept study conducted in laboratory animals, which is an important early step in medical research. The findings are promising but preliminary. The dye’s performance matched standard diagnostic markers, suggesting the approach is scientifically sound. However, animal studies don’t always translate to humans, and significant additional research would be needed before this could be used clinically. The research was published in ACS Sensors, a peer-reviewed scientific journal, indicating it underwent expert evaluation.
What the Results Show
The new dye successfully detected liver damage in all three disease models tested in mice. In acetaminophen-induced acute liver injury, the dye showed rapid changes in glow intensity that correlated with liver enzyme levels in the blood—a standard marker of liver damage. In carbon tetrachloride-induced fibrosis (liver scarring), the dye detected progressive changes as the liver developed scar tissue over time. In diet and drug-induced steatosis (fatty liver), the dye identified the accumulation of fat in liver cells.
Crucially, the dye’s signal decreased after treatment was given, suggesting it could track whether treatments are working. This real-time feedback capability is important because it would allow doctors to see immediately if a therapy is helping, rather than waiting weeks for blood test results.
The intensity of the glow directly correlated with standard histological markers—tissue samples examined under a microscope by pathologists. This validation against established diagnostic methods strengthens confidence that the dye is measuring something biologically meaningful.
The research demonstrated that the dye’s water-soluble formulation (the PEG component) allows it to circulate properly in the body and accumulate specifically in the liver. The near-infrared II wavelength (1000-1700 nanometers) provided superior tissue penetration compared to visible light, meaning the signal could be detected from deeper within the body. The dye maintained its viscosity-sensing properties even in the complex biological environment of living tissue, which is a significant technical achievement.
Previous molecular rotors—dyes designed to change brightness based on environmental conditions—have been limited to visible or near-infrared I light, which doesn’t penetrate tissue as effectively. This is the first report of a water-soluble NIR-II molecular rotor optimized for liver imaging. The approach builds on decades of research in fluorescent imaging but represents a meaningful advance in sensitivity and tissue penetration. Existing liver imaging methods like ultrasound and MRI provide structural information but cannot detect the microscopic viscosity changes that precede visible damage.
This research was conducted only in mice, and animal models don’t always predict human outcomes. The study didn’t specify the exact number of animals used or provide detailed statistical analysis of variability between individual mice. The dye has not been tested in humans, so its safety profile in people is unknown. The research focused on acute and chronic liver damage but didn’t explore whether the dye could detect early, subtle changes before significant damage occurs. Additionally, the practical challenges of translating this to clinical use—including regulatory approval, manufacturing scale-up, and cost—remain unaddressed.
The Bottom Line
This research is too preliminary for any clinical recommendations. It demonstrates proof-of-concept in animals and suggests the approach warrants further development. If you have liver disease or risk factors, continue following your doctor’s current diagnostic recommendations (blood tests, ultrasound, or biopsy as appropriate). Do not expect this technology to be available for clinical use in the near future.
This research is most relevant to hepatologists (liver specialists), medical imaging researchers, and pharmaceutical companies developing liver disease treatments. Patients with liver disease should be aware of emerging diagnostic tools but should not delay current medical care waiting for new technologies. People at risk for liver disease (heavy alcohol users, those with hepatitis, or taking medications that affect the liver) should maintain regular monitoring with established methods.
Realistic timeline for clinical availability: 5-10+ years minimum. The research must progress through additional animal studies, toxicology testing, regulatory review, and human clinical trials before any potential approval. Even optimistic scenarios would require several years of additional development.
Frequently Asked Questions
Can this new liver imaging dye be used in humans right now?
No, this technology is still in early research stages using mice only. Significant additional testing, safety studies, and regulatory approval would be required before any human use. This typically takes 5-10+ years minimum from the current stage.
How does this glowing dye detect liver damage differently than current tests?
Current liver tests measure chemicals in the blood after damage occurs. This dye detects microscopic changes in liver tissue texture before major damage develops, potentially enabling earlier diagnosis. The dye glows brighter or dimmer based on how thick the fluid around liver cells becomes.
What types of liver disease can this dye detect?
In mice, the dye detected acute liver injury from acetaminophen, liver scarring from toxic chemicals, and fatty liver disease from diet and drugs. Whether it can detect other liver conditions like hepatitis or cirrhosis remains unknown and would require additional research.
Is this better than ultrasound or MRI for detecting liver problems?
This dye detects microscopic chemical changes that ultrasound and MRI cannot see, potentially catching disease earlier. However, it’s still experimental in animals. Current imaging methods remain the standard for clinical diagnosis until this technology completes human testing.
When will doctors be able to use this dye to diagnose liver disease?
Clinical availability is likely 5-10+ years away at minimum. The dye must complete additional animal studies, safety testing, human clinical trials, and regulatory approval before doctors can use it in patients. Current diagnostic methods should continue to be used.
Want to Apply This Research?
- If this technology becomes clinically available, users could track liver health markers over time by logging imaging results and correlating them with lifestyle factors (alcohol consumption, medication use, diet quality) to identify patterns that affect liver function
- Users at risk for liver disease could use the app to set reminders for medical check-ups and log behaviors that affect liver health (alcohol intake, medication adherence, exercise, diet), creating accountability for liver-protective habits
- Long-term tracking would involve periodic imaging results (if/when available clinically) combined with standard blood tests, allowing users to visualize trends in liver health over months and years while working with their healthcare provider
This research describes an experimental imaging technology tested only in laboratory mice. It is not approved for human use and is not available clinically. This article is for educational purposes and should not be interpreted as medical advice. If you have liver disease or concerns about liver health, consult with a qualified healthcare provider about appropriate diagnostic and treatment options. Do not delay or avoid current medical care based on this emerging research.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.